We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Vircell S.L.

Vircell is a biotechnology company specialized in the development and production of ready-to-use reagents for the dia... read more Featured Products: More products

Download Mobile App




Commercial Kits Evaluated for Mediterranean Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 16 Apr 2020
Human visceral leishmaniasis (VL) is a neglected disease endemic in the Mediterranean region, caused by Leishmania infantum. More...
Accurate VL diagnosis is critical for rapid and correct patient management. Dogs are the main reservoir of L. infantum parasites that are transmitted to humans by the bite of infected phlebotomine sand flies.

Parasite detection by microscopic examination of bone marrow aspirates is the gold standard method, but lacks sensitivity and requires invasive procedures. The culture of parasites isolated from patients might improve the diagnostic sensitivity. Various methods are used for VL serodiagnosis and molecular tests have been employed.

A team of scientists at the Université de Montpellier (Montpellier, France) and their international colleagues tested serum samples from 319 patients living in France, Tunisia or Morocco. The population of 181 with proven VL included 65 immunocompromised patients.

The serum samples were tested with two immunochromatographic tests (ICT): IT LEISH and TruQuick LEISH IgG/IgM (Meridianbioscience, Cincinnati, OH, USA) and four enzyme-linked immunosorbent assay (ELISA) reagents: NovaLisa Leishmania infantum IgG (NovaTec Immundiagnostica GmbH, Dietzenbach, Germany); Bordier Leishmania infantum (Bordier Affinity Products SA, Crissier, Switzerland); Ridascreen Leishmania IgG (R-Biopharm AG, Darmstadt, Germany); and Vircell Leishmania (Vircell, Granada, Spain).

The team reported that significantly higher percentages of false-negative results were obtained with all assays in immunocompromised patients, compared with the immunocompetent population. In the whole population, sensitivity and specificity ranged from 80.7% to 93.9% and from 95.7% to 100%, respectively. The maximum accuracy was observed with the Bordier and Vircell ELISA kits (96.2%), and the lowest accuracy with Ridascreen reagent (88.7%). New thresholds of positivity are proposed for the Bordier, Vircell and NovaLisa ELISA kits to achieve 95% sensitivity with the highest possible specificity. Western blot (WB), used as a confirmation method, showed 100% sensitivity and identified 10.1% of asymptomatic carriers among the control population from the South of France.

The authors concluded that the Vircell and Bordier ELISA kits displayed significantly higher accuracy rates in the whole population than the other tests. For field studies, the TruQuick ICT is the most suitable with satisfactory performances. In immunocompromised patients, the index values of all ELISA reagents were significantly lower than in the immunocompetent population and false-negative results were more frequent. The study was published on March 25, 2020 in the journal PLOS Neglected Tropical Diseases.



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.